- Exchange: Natl India
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Glenmark Pharmaceuticals Ltd
+ Add to WatchlistGNP:IN
549.30 INR 22.70 3.97%As of 05:04:55 ET on 05/24/2013.
Snapshot for Glenmark Pharmaceuticals Ltd (GNP)
| Open: | 570.00 | Day's Range: | 546.25 - 570.00 | Volume: | 571,651 |
|---|---|---|---|---|---|
| Previous Close: | 572.00 | 52wk Range: | 341.70 - 609.00 | 1-Yr Rtn: | +55.83% |
Key Statistics for GNP
| Current P/E Ratio (ttm) | 24.1986 |
|---|---|
| Estimated P/E(03/2014) | 19.3633 |
| Relative P/E vs. SENSEX | 1.4657 |
| Earnings Per Share (INR) (ttm) | 22.7100 |
| Est. EPS (INR) (03/2014) | 28.3810 |
| Est. PEG Ratio | 0.6971 |
| Market Cap (M INR) | 148,871.14 |
| Shares Outstanding (M) | 270.90 |
| 30 Day Average Volume | 661,265 |
| Price/Book (mrq) | 5.3939 |
| Price/Sale (ttm) | 2.9716 |
| Dividend Indicated Gross Yield | 0.36% |
| Cash Dividend (INR) | 2.0000 |
| Last Dividend | |
| 5 Year Dividend Growth | 7.39% |
| Next Earnings Announcement | 08/02/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for GNP
Company Profile & Key Executives for GNP
Glenmark Pharmaceuticals Ltd., is a pharmaceutical company. The Company develops generic drugs for inflammation, metabolic disorders, and pain.
| Glenn Mario SaldanhaChairman/Managing Director | Rajesh V DesaiChief Financial Officer |
| Marshall J MendonzaVP/Joint Secretary | Cherylann Maria PintoDirector:Corp Affairs |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
GNP News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page